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Transmembrane mucins are glycoproteins involved in
barrier function in epithelial tissues. To identify novel
transmembrane mucin genes, we performed a tblastn
search of the GenBanky EST data bases with a serine/
threonine-rich search string, and a rodent gene ex-
pressed in bone marrow was identified. We determined
the cDNA sequence of the human orthologue of this
gene, MUC13, which localizes to chromosome band
3q13.3 and generates 3.2-kilobase pair transcripts en-
coding a 512-amino acid protein comprised of an N-ter-
minal mucin repeat domain, three epidermal growth
factor-like sequences, a SEA module, a transmembrane
domain, and a cytoplasmic tail (GenBanky accession no.
AF286113). MUC13 mRNA is expressed most highly in
the large intestine and trachea, and at moderate levels
in the kidney, small intestine, appendix, and stomach. In
situ hybridization in murine tissues revealed expression
in intestinal epithelial and lymphoid cells. Immunohis-
tochemistry demonstrated the human MUC13 protein
on the apical membrane of both columnar and goblet
cells in the gastrointestinal tract, as well as within gob-
let cell thecae, indicative of secretion in addition to
presence on the cell surface. MUC13 is cleaved, and the
b-subunit containing the cytoplasmic tail undergoes ho-
modimerization. Including MUC13, there are at least
five cell surface mucins expressed in the gastrointesti-
nal tract.
The epithelial mucins are a family of secreted and cell-surface
glycoproteins expressed by ductal and glandular epithelial tis-
sues. Members of this family are characterized by a tandem
repeat structure, which comprises most of the protein backbone
and is the scaffold for a large number of complex O-linked car-
bohydrate side chains. Twelve human epithelial mucin genes
have been identified to date, and it is now clear that there are two
structurally and functionally distinct classes of mucins: secreted
gel-forming mucins and transmembrane mucins.
Gel-forming mucins are secreted by goblet cells and are the
major constituent of mucus, which protects and lubricates ep-
ithelial surfaces, particularly those of the gastrointestinal, res-
piratory and reproductive tracts. These mucins undergo homo-
oligomerization and are clearly the critical contributors to the
biophysical properties of mucus (1). The gel-forming mucins are
encoded by a cluster of four mucin genes (MUC2, MUC5AC,
MUC5B, and MUC6) on chromosome band 11p15.5 (2). The
MUC7 gene encodes a relatively small secreted salivary mucin
(3), and MUC9 is a relatively small secreted mucin expressed
only in the Fallopian tube (4). The MUC8 cDNA, expressed in
respiratory tissue, has not been well characterized (5).
It has recently emerged that there is a large family of
epithelial transmembrane mucins, many members of which
are highly expressed in the gastrointestinal tract, particu-
larly in the large intestine. The MUC1 gene encodes a trans-
membrane mucin expressed by almost all human glandular
epithelial tissues and throughout all regions of the gastroin-
testinal tract (6). The MUC3 and MUC4 genes were initially
thought to encode secreted mucins; however, it has recently
been shown that these genes encode transmembrane mucins
as their dominant isoforms (7, 8). There is a newly identified
cluster of transmembrane mucin genes located on chromo-
some band 7q22 (9). Members of this cluster include the
closely related MUC3 and MUC12 genes (10, 9). MUC3 is
most highly expressed in the small intestine, whereas
MUC12 is most highly expressed in the colon (9). Further
genes may also lie in this cluster, and the genomic organiza-
tion of these genes should be clarified shortly by the Human
Genome Project. The MUC4 gene located on chromosome
band 3q29 appears to be related to genes in the 7q22 cluster,
as the mucin it encodes contains a similar domain structure
and, although most highly expressed in the tracheobronchus,
is also present in the intestine (8, 11).
Common structural features shared by all the identified
transmembrane mucins include C-terminal cytoplasmic do-
mains with motifs suggestive of a role in signal transduction,
a SEA module in the extracellular domain (12), and a large
mucin domain at the N terminus of the extracellular subunit.
The two mucins studied biochemically to date, human MUC1
and rat Muc4, undergo cleavage and non-covalent reassocia-
tion during biosynthesis, with disruption of this association
allowing shedding of the mucin domain from the cell surface
(13, 14). Thus, the ability to shed a large mucin protein from
the cell surface and the ability to transmit signals have both
been heavily conserved. In addition, MUC3, MUC4, and
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MUC12 all contain two cysteine-rich EGF1-like domains, one
to either side of the SEA module. The function of EGF-like
motifs in these mucins is unclear, although there is evidence
implicating these domains in epithelial growth modulation (15).
In the present investigation, we have used data base mining
to identify a novel human transmembrane mucin gene that has
been designated MUC13 by the HUGO Gene Nomenclature
Committee. The rodent orthologues of MUC13 have been pre-
viously identified and were thought to be restricted to expres-
sion in hemopoietic precursor cells in bone marrow (16). We
describe the cDNA sequence of human MUC13 and show that
the putative protein has the same domain organization as
MUC3, MUC4, and MUC12, and similarities to MUC1. We also
demonstrate that both the human and mouse genes are ex-
pressed predominantly in epithelial tissues, particularly those
of the gastrointestinal tract, and demonstrate the human pro-
tein on the epithelial apical membrane and within goblet cell
thecae of gastrointestinal epithelia. Initial biochemical charac-
terization indicates that MUC13 is cleaved into two subunits
and that the subunit containing the cytoplasmic tail undergoes
homodimerization.
EXPERIMENTAL PROCEDURES
Identification and Cloning of the Human MUC13 cDNA—A serine/
threonine-rich search string, TTXXSXSPGSXSPXSTTT, was employed
in an advanced parameter tblastn search of the National Center of
Biotechnology Information human and mouse EST data bases. A match
in the mouse EST data base led to the identification of a known full-
length cDNA, named 114/A10. Examination of the human EST data
base identified partial sequences of the putative human orthologue of
this gene. Using a combination of sequencing ESTs and RT-PCR, a
2.9-kb cDNA composite of the human gene was obtained (see “Results”).
RNA Expression Analyses—RNA was extracted from cell lines and
human tissue specimens using Trizol (Life Technologies, Inc., Mul-
grave, Victoria, Australia) as per the manufacturer’s instructions.
Northern blot analysis was performed using standard protocols (17) on
total RNA isolated from five colorectal cancer cell lines (LIM2463, LoVo,
LS513, Caco-2, and SW116) and from 12 paired normal colonic mucosa
and tumor tissues and 7 liver metastases, Dukes’ A (n 5 4), Dukes’ B
(n 5 3), Dukes’ C (n 5 4), and Dukes’ D (n 5 7). Informed consent was
obtained from each subject after approval by the Princess Alexandra
Hospital Ethics Committee. A MUC13 probe (base pair sequence 673–
1756 in Fig. 1) was random primer-labeled using a Megaprime DNA
labeling system (Amersham Pharmacia Biotech, Aylesbury, United
Kingdom) and hybridized to Northern blots at 65 °C in buffer contain-
ing 7% SDS, 0.26 M Na2HPO4, 1 mM EDTA, and 1% bovine serum
albumin.
A human RNA Multiple Tissue Expression Array (CLONTECH, Palo
Alto, CA, catalogue no. 7775-1) was used to examine MUC13 expression
in normal human tissues (RNA from 71 adult tissues, 7 fetal tissues,
and 8 cancer cell lines). The MUC13 cDNA probe (as above) was hy-
bridized as per the manufacturer’s instructions. Levels of expression
were quantitated using a scanning densitometer and Molecular Analyst
software (Bio-Rad, Regents Park, New South Wales, Australia). Signal
intensity was expressed relative to the sample with highest levels of
expression since loading of RNA samples on the array had previously
been normalized using eight housekeeping genes by the manufacturer.
Mouse intestinal cDNA was amplified by RT-PCR to yield a 768-base
pair PCR product (corresponding to nucleotides 182–950 in GenBanky
accession no. J04634) that was cloned into pGEM-T and sequenced.
Riboprobes were made by in vitro transcription of DNA with T7 and SP6
RNA polymerases and incorporation of digoxigenin-labeled uridine
triphosphate (Roche, Castle Hill, New South Wales, Australia). Ap-
proval for collection of animal tissues was obtained from the University
of Queensland Animal Experimentation Ethics Committee. Murine ep-
ithelial tissues and spleen were fixed for 4 h in fresh 4% paraformal-
dehyde in 10 mM phosphate-buffered saline, pH 7.2 (PBS), embedded in
paraffin, and sectioned. Hybridization and washing conditions were
modified from that described previously (18). Antisense and sense
probes at 1 mg/ml in ULTRAhyb (Ambion, Austin, TX) were hybridized
to sections overnight at 48 °C. The reaction was visualized with 4-bro-
mo-5-chloro-3-indolyl phosphate and nitro blue tetrazolium substrate
(Roche) also overnight. Sections were counterstained with nuclear fast
red, dehydrated, cleared, and mounted in DePeX.
Chromosomal Localization of MUC13 by Fluorescence in Situ Hy-
bridization—The MUC13 cDNA probe (as above) was nick-translated
with biotin-14-dATP and hybridized in situ at a final concentration of
10 ng/ml to metaphases from two normal males. The fluorescence in situ
hybridization method was modified from that described previously (19),
in that chromosomes were stained before analysis with both propidium
iodide as counterstain and 4,6-diamidino-2-phenylindole for chromo-
some identification. Images of metaphase preparations were captured
by a cooled CCD camera using the CytoVision Ultra image collection
and enhancement system (Applied Imaging Corp., Sunderland, United
Kingdom).
Production of MUC13-reactive Polyclonal Antibodies—Three syn-
thetic peptides were synthesized (Auspep, Parkville, Australia) corre-
sponding to three hydrophilic sequences of the putative MUC13 amino
acid sequence, each with an terminal cysteine residue added: an extra-
cellular domain epitope (peptide A, DPEEKHSMAYQDLHSEC (amino
acids 229–244 in Fig. 1)) and two cytoplasmic tail epitopes (peptide B,
CRSNNTKHIEEENLID (amino acids 446–461 in Fig. 1); and peptide
C, CMQNPYSRHSSMPRPDY (amino acids 497–512 in Fig. 1)). These
peptides were conjugated to bovine serum albumin using glutaralde-
hyde (20). Six-week-old female BALB/c mice were immunized intrap-
eritoneally with 25 mg of conjugated peptide initially in 0.2 ml of
complete Freund’s adjuvant/PBS 1:1 (Life Technologies Inc.), and then
at 3-week intervals in incomplete Freund’s adjuvant. Blood samples
were obtained via cardiac puncture under terminal anesthesia, clotted,
and serum stored at 220 °C. Reactivity of serum with the peptides was
assessed using the specific and irrelevant unconjugated peptides as
solid phase in an enzyme-linked immunosorbent assay. All animal
experiments were approved by the University of Queensland Animal
Experimentation Ethics Committee.
Immunohistochemical Detection of Human MUC13 in Epithelial Tis-
sues—Polyclonal MUC13 peptide-reactive mouse sera were used to
detect MUC13 in paraffin sections of normal and diseased human
gastrointestinal epithelial tissues. Immunohistochemical techniques
were as described previously (21) with peptide A and B reactive sera
diluted 1/100 and tissue sections subject to antigen retrieval by boiling
in 0.1 M citric acid, pH 6, and peptide C reactive sera diluted 1/400 with
antigen retrieval not used.
Biochemical Characterization of the MUC13 Protein—Colorectal can-
cer cell lines LIM2463 and LS513 were maintained in RPMI 1640
containing 10% fetal bovine serum, and routinely passaged by trypsin
digestion. Monolayers of cells were washed with ice-cold PBS and lysed,
with rocking for 30 min, using a variety of ice-cold lysis buffers includ-
ing: RIPA (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxy-
cholate, 1 mM PMSF, pH 7.5), Nonidet P-40 (50 mM Tris, 150 mM NaCl,
0.5% Nonidet P-40, 1 mM PMSF, pH 7.5), BRIJ97 (50 mM Tris, 150 mM
NaCl, 0.5% Brij97, 1 mM aprotinin, pH 7.6), and TX100 (50 mM Tris, 150
mM NaCl, 0.5% Triton X-100, 1 mM PMSF, pH 7.5). Cell surface proteins
were biotinylated by incubating cell monolayers with 0.5 mg/ml bioti-
namidocaproic acid 3-sulfo-N-hydroxysuccinimide (Sigma) in PBS with
0.1 mM CaCl2 and 1 mM MgCl2, followed by lysis as above. MUC13 was
immunoprecipitated with polyclonal antisera against peptides A (1/100
dilution), B (1/100), or C (1/400) or with antisera raised against irrele-
vant conjugated peptides as a control, using previously described meth-
ods (22). For removal of N-linked glycans, immunoprecipitates were
denatured in 0.5% SDS, 0.1 M 2-mercaptoethanol for 5 min at 100 °C,
reconstituted to 0.15 M Tris, 0.16% SDS, 1.6% Nonidet P-40, pH 7.5, and
100 units/ml PNGase F (Roche) for 24 h at 32 °C. Crude lysates, im-
munoprecipitated biotinylated cell surface proteins and deglycosylated
immunoprecipitates were prepared in SDS-PAGE buffer containing 2%
SDS, with and without 5% 2-mercaptoethanol, subjected to electro-
phoresis either in 4–20% gradient or 10% resolving gels with 3% stack-
ing gels, and electrotransferred to polyvinylidene difluoride or nitrocel-
lulose membranes as described (22). Benchmarky prestained Mr
markers were included on each gel (Life Technologies, Inc.). Western
blotting was performed as described previously (22). Briefly, mem-
branes were blocked with 10% skim milk powder and MUC13 was
detected using polyclonal antisera against peptides A (1/400 dilution), B
(1/400), or C (1/4000) followed by donkey anti-mouse horseradish per-
oxidase conjugate (Jackson Laboratories) and ECL detection (Amer-
1 The abbreviations used are: EGF, epidermal growth factor; CF,
cystic fibrosis; PBS, phosphate-buffered saline; PCR, polymerase chain
reaction; EST, expressed sequence tag; PAGE, polyacrylamide gel elec-
trophoresis; RT, reverse transcription; kb, kilobase pair(s); PMSF,
phenylmethylsulfonyl fluoride; PNA, A. hypogaea lectin; HPA, H. po-
matia lectin; RIPA, radioimmune precipitation buffer; PNGase F, Pep-
tide: N-glycosidase F.
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sham Pharmacia Biotech). Specific carbohydrates were detected using 2
mg/ml Helix pomatia and Arachis hypogaea lectins (Sigma). Immuno-
precipitated biotinylated proteins and biotinylated lectins were de-
tected with streptavidin-horseradish peroxidase conjugate (Zymed Lab-
oratories Inc., San Francisco, CA) diluted 1/2000 followed by ECL
detection.
RESULTS
Identification and Cloning of the Human MUC13
cDNA—Serine/threonine-rich search strings based on known
mucin protein sequences were employed in tblastn searches of
the NCBI human and mouse EST data bases in a search for
previously unidentified mucin genes. Using one such string
(TTXXSXSPGSXSPXSTTT), a number of matches with the
mouse data base revealed the previous identification and clon-
ing of a rodent gene encoding a bone marrow glycoprotein
designated 114/A10, or mouse cell surface antigen. 114/A10
appeared similar to known epithelial transmembrane mucins,
containing a series of eight highly conserved serine/threonine-
rich 27 amino acid repeats leading into three EGF-like do-
mains, a transmembrane region, and a cytoplasmic tail (Gen-
Banky accession no. J04634) (16). Partial cDNA sequences
encoding protein sequences similar to 114/A10 were also evi-
dent in the human EST data base (e.g. GenBanky accession
nos. AI949096, AI821099, and AI431674). The domain organi-
zation of 114/A10 was very similar to the human MUC3,
MUC4, and MUC12 transmembrane mucin genes, and prelim-
inary RT-PCR indicated expression in human epithelial tis-
sues. Therefore, we pursued complete human cDNA cloning
and expression analysis of this gene in human and rodent
tissues.
The cDNA sequence of the human mucin gene was extended
in both 59 and 39 directions by a combination of EST sequencing
and RT-PCR. The HUGO Gene Nomenclature Committee has
designated this gene MUC13. The complete cDNA sequence
and the putative amino acid sequence of MUC13 are shown in
Fig. 1. The putative human precursor polypeptide comprises
512 amino acids with a predicted molecular mass of 54,703 Da
and has an identical domain structure (exemplified in Fig. 2) to
the previously described murine protein (16). At the N termi-
nus is a signal peptide for the secretory pathway with cleavage
predicted between residues 19 and 20 (23). The signal peptide
is followed by a serine- and threonine-rich domain likely to
involve extensive O-glycosylation (amino acid residues 20–170)
consisting of 10 degenerate tandem repeats. Following this
mucin domain are two distinct cysteine-rich domains contain-
ing EGF-like motifs. Separating the two cysteine-rich domains
are 115 amino acids comprising a SEA module (amino acid
residues 212–328). The first cysteine-rich domain contains one
EGF-like sequence EGF1 (amino acid residues 177–210), and
the second larger cysteine-rich domain contains two EGF-like
FIG. 1. Complete cDNA sequence and predicted amino acid
sequence of human MUC13 (GenBanky accession no.
AF286113). Numbering of nucleotides is given on the left and amino
acids on the right. The signal peptide is underlined, and seven potential
N-glycosylation sites are double underlined. All cysteine residues and
the entire transmembrane domain are enclosed in a box. A non-consen-
sus and consensus polyadenylation signal in the 39-untranslated region
are underlined.
FIG. 2. Schematic representation of the putative domain orga-
nization of the human MUC13 protein. The number of amino acids
(aa) in each domain is shown.
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sequences, EGF2 (amino acid residues 326–360) and EGF3
(amino acid residues 367–403). EGF3 contains a type II EGF
signature (amino acid residues 389–403) and is followed
closely by a 23-amino acid transmembrane domain and a 69-
amino acid cytoplasmic tail. In addition to extensive potential
O-glycosylation sites in the mucin domain, there are six extra-
cellular and one intracellular consensus motifs for N-glycosy-
lation. The cytoplasmic tail contains a protein kinase C con-
sensus phosphorylation motif (amino acid residues 444–447),
and eight serine residues and two tyrosine residues that may
undergo phosphorylation and regulate MUC13 signaling.
Expression of MUC13 in Colorectal Cancers and Colorectal
Cancer Cell Lines—Northern blot analysis of colonic tissues
showed a single band indicating the size of the human mRNA
to be ;3.2 kb (see Fig. 3). Analysis of 12 paired samples of
normal colonic and primary tumor tissues and seven liver
metastases revealed MUC13 expression in most colorectal can-
cers examined (Fig. 3). There was evidence for down-regulation
of expression (,20% of normal colonic expression level) in three
of four Dukes’ C tumors and two of seven Dukes’ D tumors.
There was a 2.5-fold increase in expression of MUC13 in one
Dukes’ stage B tumor. MUC13 was expressed at varying levels
in the six colorectal cancer cell lines under investigation, with
highest levels of expression in LIM2463 cells and compara-
tively low levels of expression observed in the Caco-2 cells (data
not shown).
Both the human and rodent genes contain a series of CA
dinucleotide repeats and an alternative polyadenylation signal
in the 39-untranslated region. mMuc13 has previously been
shown, in some IL-3 dependent cell lines, to produce two tran-
scripts, of ;2.2 and 3 kb, generated by use of two distinct
polyadenylation signals (22). Northern blot analyses of MUC13
in colorectal cancer cell lines and colonic tissues only revealed
a single band of about 3.2 kb. However, an EST (GenBanky
accession no. AI431674) appears to have been derived from
alternative use of the non-consensus polyadenylation signal,
suggesting that smaller human MUC13 transcripts do exist,
but are probably rare.
Fluorescence in Situ Hybridization—Chromosomal localiza-
tion studies using fluorescence in situ hybridization mapped
the human gene to chromosome band 3q13.3 (Fig. 4A).
Comparison of Human MUC13 with Rat and Mouse Ortho-
logues—Amino acid alignment of the C terminus of the human
MUC13 mucin with its rodent orthologues revealed 52% iden-
tity to its mouse and rat counterparts (see Fig. 5). The N-
terminal mucin domain shows significant divergence from the
rodent proteins, which possess a near perfect repeat structure
compared with the very degenerate repeats seen in the human
protein, although the mucin domains are approximately the
same size. The seven C-terminal amino acids of the cytoplasmic
domain, including a terminal tyrosine residue, are perfectly
conserved in all three species.
Expression of MUC13 mRNA in Human Tissues—Hybridiza-
tion of MUC13 using a multiple tissue expression array dem-
onstrated that MUC13 is expressed at highest levels in the
large intestine and the trachea, and is also expressed at rela-
tively high levels in the kidney, small intestine, appendix, and
stomach (see Fig. 6). After long exposures, low levels of expres-
sion were also identified in pancreas, prostate, uterus, lung,
liver, adrenal gland, spleen, peripheral blood leukocytes, lymph
node, bone marrow, testis, and ovary. MUC13 was not detected
in 21 different neural tissues, eight cardiovascular tissues,
esophagus, thyroid gland, salivary gland, mammary gland,
skeletal muscle, placenta, or urinary bladder. Fetal kidney
expressed moderately high levels of MUC13, and low levels
were seen in fetal spleen, lung, thymus, and liver. Fetal heart
and brain did not express MUC13, and other fetal tissues, such
as gastrointestinal tissues, were not represented on this array.
Two of eight cancer cell lines, one derived from a colorectal
cancer, SW620, and the other from a lung cancer, A549, showed
moderately high levels of MUC13 expression.
Cellular Localization of MUC13 in Normal Murine Tis-
sues—In situ hybridization using digoxigenin-labeled ribo-
probes in murine tissues revealed highest levels of expression
in the large intestine. In the large intestine and rectum,
MUC13 mRNA was seen in both columnar and goblet cells deep
in the crypts, with lower levels of expression in some cells of the
surface epithelium (Fig. 4, B–E). A large proportion of cells
within lymphoid tissue associated with the distal large intes-
tine and rectum also showed high levels of expression (Fig. 4F).
MUC13 was also detected in the villi of the murine small
intestine, in gastric glands and the surface epithelium of the
stomach, and in the squamous epithelium of the esophagus
(data not shown). Pancreatic acini and ducts also expressed low
levels of MUC13, as did pneumocytes in the lung and both
bronchiolar and tracheal epithelium (data not shown). How-
ever, MUC13 mRNA was not detected in the liver or kidney.
Clusters of lymphoid cells in both the red pulp and, to a lesser
extent, the follicles of the spleen expressed MUC13 (data not
shown).
Antisera Reactive with the Human MUC13 Protein—Murine
antisera were produced that were reactive in enzyme-linked
immunosorbent assay with the A, B, and C peptide epitopes
based on the putative MUC13 sequence. The highest titer was
achieved against the C peptide with sera reactive at greater
than 1/50,000 dilution. These antisera also reacted with
MUC13 by immunohistochemistry with paraffin sections, in
immunoprecipitation and Western blotting (see below), and by
flow cytometry (data not shown).
Cellular Localization of MUC13 in Human Gastrointesti-
nal Tissues—Polyclonal antisera raised against peptides A,
B, and C reacted similarly with paraffin sections of fixed
human gastrointestinal tissues, with the peptide C-reactive
antisera showing the best reactivity and not requiring anti-
gen retrieval of sections. Surprisingly, given the lack of re-
activity on the human mRNA master blot, intense MUC13
staining was observed in the cytoplasm of squamous epithe-
lial cells of the esophagus, with staining absent or very weak
in the basal cell layer (see Fig. 4G). In the body of the
stomach, MUC13 was expressed on the apical membrane
surface of cells of the surface epithelium, the gastric pits, and
the more peripheral glands but only occasionally in the deep
glands (see Fig. 4H). In addition, in the gastric glands, occa-
FIG. 3. Northern blot analysis of MUC13 gene expression in
matched normal colon (N) and primary colorectal cancers (P),
in individual Dukes’ stage D tumors (M) and normal liver (NL).
The 3.2-kb MUC13 band is shown in the upper panels, and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) is shown as a loading con-
trol in each lower panel. Cancers showing down-regulation are indi-
cated by an asterisk.
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sional mucus neck cells showed intense granular cytoplasmic
staining (see Fig. 4H). Some mucus cells of the surface epi-
thelium and gastric pits also showed moderate cytoplasmic
reactivity, and in some cells supranuclear staining was also
observed. In the pyloric and cardiac stomach, some of the
deep glands showed moderate to strong cytoplasmic expres-
sion of MUC13, whereas adjacent glands were often negative
(Fig. 4I). In the duodenum, MUC13 was detected in supranu-
FIG. 4. In situ hybridization and immunohistochemistry. A, chromosomal metaphase spread showing localization of MUC13 to chromo-
some band 3q13.3. B–F, murine tissue sections hybridized with MUC13 sense (B) and antisense (C–F) digoxigenin-labeled probes detected using
4-bromo-5-chloro-3-indolyl phosphate and nitro blue tetrazolium (blue/purple) and counterstained with nuclear fast red. Tissues shown: rectum
(B and C), distal large intestine (D), proximal large intestine (E), rectum and associated lymphoid tissue denoted by arrow (F). G–O, human tissues
stained with mouse anti-sera reactive with the C peptide epitope of the MUC13 cytoplasmic tail detected using diaminobenzidine (brown) and
counterstained with hematoxylin (blue; see “Experimental Procedures”). Tissues shown are esophagus (G), surface epithelium, gastric pits, and
peripheral glands of the body of the stomach (H), deep glands of the pyloric stomach (I), villi of the duodenum (J), deep glands of the terminal ileum
(K), villi of the terminal ileum (L), appendix (M), deep glands of the colon (N), and a colorectal carcinoma liver metastasis (O). Original
magnifications were as follows: B and C, 355; D–F, 3220; G and H, 3110; I–O, 3220.
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clear vacuoles within all absorptive cells, consistent with
detection in the Golgi region; however, apical membrane
staining was not seen (see Fig. 4J). MUC13 was also ex-
pressed on the apical membrane of epithelial cells lining
pancreatic ducts (data not shown).
In the terminal ileum of the small intestine, MUC13 was
detected as intense staining of the apical membrane of all cells
deep in the crypts (see Fig. 4K) and less frequent apical mem-
brane staining of cells of the surface epithelium (see Fig. 4L).
Both goblet and columnar cells appeared to express cell surface
MUC13; however, staining was more intense in columnar cells,
and, at high power, a microvillous-type pattern was observed.
Secreted material in the crypt lumen also stained. In addition,
moderate to weak staining in mesh network and punctate
patterns was also seen within the thecae of goblet cells in the
villi (see Fig. 4L) but only rarely deep in the crypts (see Fig.
4K). The staining of goblet cell thecae was more pronounced
using peptide A-reactive antisera than C-reactive antisera
(data not shown). Appendix showed strong MUC13 immunore-
activity both in the cytoplasm and on the cell surface of both
goblet and columnar cells, with very strong cytoplasmic reac-
tivity in columnar cells (see Fig. 4M). In the colon, MUC13 was,
similarly to the terminal ileum, highly expressed on the apical
membrane surface of both columnar and goblet cells deep in the
crypts (see Fig. 4N). In addition, supranuclear vacuolar stain-
ing, like that seen in the duodenum, was also observed in these
cells together with reactivity with secreted material. Occa-
sional columnar cell apical membrane staining was observed on
the colonic surface epithelium together with goblet cell thecal
staining, although this was less intense than that seen in the
terminal ileum.
In a small series of colorectal cancers examined, MUC13 was
expressed in the cytoplasm and on the cell surface of cancer
cells; however, expression of MUC13 was often low relative to
normal tissue and was typically heterogeneous in nature (see
Fig. 4O). Only very rarely did non-epithelial cells in the stroma
or lymphoid patches of intestinal tissues show weak membrane
staining for MUC13 (data not shown).
Biochemical Characterization of the Human MUC13 Pro-
tein—Lysates of LIM2463 and LS513 colorectal cancer cells,
shown to have high MUC13 mRNA, were lysed with RIPA and
subjected to Western blotting with antisera reactive with pep-
tides A, B, and C. The two cell lines and three antisera showed
identical band patterns. Under non-reducing conditions, two
bands of ;47 and 93 kDa were observed. The 47-kDa band was
more intense than the 93-kDa band in both cell lines. However,
following reduction a single band of 58 kDa was observed (see
Fig. 7). This is consistent with the 58-kDa band representing
the 47-kDa non-reduced MUC13 protein migrating more slowly
following denaturation by reduction of the EGF-like cysteine-
rich domains likely to be involved in intrastrand disulfide
bonds. The 93-kDa non-reduced band may represent associa-
tion of the MUC13 47-kDa protein with another protein. How-
ever, it is more likely, given that it is almost twice the mass of
the 47-kDa protein, that the 93-kDa band represents a MUC13
homodimer. This association is clearly dependent on either
intra- or intermolecular disulfide linkages. Identical reactivity
of all three antisera demonstrates that the A, B, and C epitopes
are present in the same MUC13 polypeptide. Cell surface-
biotinylated MUC13 in LIM2463 and LS513 cells was immu-
noprecipitated by A, B, or C peptide-reactive antisera and
showed identical reduced and non-reduced banding patterns to
those shown in direct Western blotting, confirming MUC13 as
a cell surface protein (see Fig. 8).
Because it was suspected that MUC13 may be cleaved into
two subunits and because these subunits may disassociate
from each other in harsh detergents, as has been demon-
strated for MUC1 (22), we also immunoprecipitated MUC13
in several lysis buffers utilizing milder detergents. Using the
milder detergents under non-reducing conditions, in addition
to the 47- and 93-kDa bands, a prominent high molecular
mass band at ;520 kDa was observed (see Fig. 9). This band
was not present following reduction; however, an intense
band at 72 kDa and a weak band at 120 kDa (Fig. 9B, arrow)
were present in addition to the 58-kDa band seen previously
in direct Western blotting.
When immunoprecipitates from non-biotinylated BRIJ97
lysates were probed with the GalNAc-reactive Helix pomatia
(HPA) and b-Gal(1,3)GalNAc-reactive Arachis hypogaea (PNA)
lectins, a single band at 120 kDa was seen with both lectins in
both LIM2463 and LS513 cells (see Fig. 10A). Treatment
of immunoprecipitated reduced biotinylated MUC13 with
PNGase F resulted in no change in the 70-kDa band. However,
the 55-kDa band disappeared and was replaced by bands at 49
and 38 kDa, demonstrating that N-glycans contributed signif-
FIG. 5. Alignment of the carboxyl termini of the human, mouse, and rat Muc13 transmembrane mucins. Light shading indicates
identical amino acids, and dark shading highlights all cysteine residues. Hyphens indicate spaces added to optimize the alignment.
FIG. 6. Relative mRNA expression of MUC13 in human tissues
determined using a multiple tissue expression array. Hybridized
arrays were subjected to densitometric analysis, and results are ex-
pressed as a percentage of the level in the highest expressing tissue,
distal large intestine. Only those tissues showing expression greater
than 5% of that in distal large intestine are shown.
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icantly to the apparent Mr of the MUC13 subunit containing
the A, B, and C epitopes in LIM2463 cells (see Fig. 10B).
DISCUSSION
The human MUC13 gene encodes an epithelial and hemo-
poietic transmembrane mucin. MUC13 is the orthologue of a
murine glycoprotein initially called 114/A10 or mouse cell sur-
face antigen and herein referred to as mMuc13. mMuc13 was
initially identified by expression cloning using an antibody
produced against a murine bone marrow-derived multipoten-
tial cell line (24). mMuc13 had previously been found to be
highly expressed in primary myeloid progenitor cells, the my-
elomonocytic leukemia cell line WEHI-3, and various interleu-
kin 3-dependent cell lines (22). Spleen, liver, muscle, and brain
tissues were assessed as not expressing mMuc13; however,
epithelial tissues were not examined.
The MUC13 gene is most highly expressed in epithelial tis-
sues, particularly those of the gastrointestinal and respiratory
FIG. 7. Western blot showing bands immunoreactive with
MUC13 peptide C-reactive antisera. LIM2463 colorectal cancer
cells were lysed with RIPA, and subjected to SDS-PAGE in a 4–20%
gradient gel both non-reduced (NR) and following reduction (R) (see
“Experimental Procedures”). Mr markers are shown at the left. The top
of the resolving gel is denoted r.
FIG. 8. Immunoprecipitation of cell surface biotinylated
MUC13 from LIM2463 and LS513 colorectal cancer cells with
antisera reactive with the A, B, or C MUC13 peptides, a combi-
nation of all three antisera, irrelevant antisera (CON), or no
primary antibody (NO 1o). Immunoprecipitates were prepared either
non-reduced (A) or reduced (B) and subjected to SDS-PAGE in 4–20%
gradient gels (see “Experimental Procedures”). Mr markers are shown
at the left. The top of the resolving gel is denoted r.
FIG. 9. Immunoprecipitation of cell surface biotinylated
MUC13 from LIM2463 colorectal cancer cells lysed with mild
detergents. Immunoprecipitation was performed with antisera reac-
tive with the MUC13 C peptide (MUC13) or irrelevant antisera (CON).
Immunoprecipitates were prepared either non-reduced (A) or reduced
(B) and subjected to SDS-PAGE in 4–20% gradient gels (see “Experi-
mental Procedures”). Mr markers are shown at the left. The top of the
resolving gel is denoted r.
FIG. 10. Glycosylation of MUC13. A, LIM2463 and LS513 colorec-
tal cancer cells were lysed with BRIJ96, immunoprecipitated with
MUC13 C peptide (MUC13) or irrelevant antisera (CON). Immunopre-
cipitates were reduced and subjected to SDS-PAGE in 3–15% gradient
gels, transferred to membranes, and probed with the HPA and PNA
lectins (see “Experimental Procedures”). B, LIM2463 colorectal cancer
cells were biotinylated, lysed with Nonidet P-40 buffer, and immuno-
precipitated with MUC13 C peptide-reactive antisera. Immunoprecipi-
tates were denatured and treated with PNGase F or in identical buffer
lacking enzyme (CONTROL) for 24 h (see “Experimental Procedures”).
Samples were reduced and subjected to SDS-PAGE in a 10% resolving
gel. Mr markers are shown at the left. The top of the resolving gel is
denoted r.
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tracts. In the large intestine, MUC13 is expressed on the apical
cell surface of both goblet and columnar cells deep in the crypts,
confirming its role as a transmembrane mucin. Presence on the
apical membrane of crypt epithelium mirrors the expression of
two other cell surface mucins, MUC1 and MUC4, which also
predominate in the crypts and are expressed by both major cell
types (25). In contrast, MUC3 (26), and MUC122 appear to be
most highly expressed by cells of the surface epithelium.
MUC13 also appears to be secreted, as we have demonstrated
its presence within goblet cell thecae and in secreted material
in the large intestine and stomach, and within supranuclear vacu-
oles, but not on the apical membrane surface, of absorptive cells in
the small intestine. This is consistent with the previous demonstra-
tion, at both light and electron microscope levels, of MUC1 associ-
ated with goblet cell secretory granules in the intestine (27).
It is now apparent that there is considerable multiplicity of
expression of these cell surface glycoproteins, especially in the
gastrointestinal tract and, in particular, the large intestine. In
fact, MUC1 and MUC13 appear to be co-expressed, both intra-
cellularly and on the same cell surfaces, in many places of the
gastrointestinal tract. However, there is evidence of differen-
tial regulation of cell surface mucins throughout the gastroin-
testinal tract. For example, although MUC1 and MUC13 ap-
pear to be expressed similarly in the colon (27) and in the
stomach (28), staining of serial sections with a MUC1-reactive
antibody revealed differing patterns of expression of MUC13
and MUC1 in gastric tissue (data not shown). As an additional
example, in the surface epithelium MUC3 is expressed most
highly in the small intestine and decreases distally with only
low expression in the distal large intestine (26). MUC12 ex-
pression increases progressively from small intestine to rec-
tum2; similarly, MUC13 mRNA expression increases from
small intestine to rectum.
In addition to multiplicity of expression, it is now apparent
that there is considerable dynamism of cell-surface mucin ex-
pression in the gastrointestinal tract. For example, as cells in
the large intestine migrate from deep in the crypts to the
surface, they must undergo a major switch in their dominant
cell surface mucin proteins from MUC1, MUC4, and MUC13 to
MUC3 and MUC12. MUC13 is also very highly expressed in
the trachea, where it is also now apparent that there is consid-
erable multiplicity of expression with MUC1 and MUC4 also
being expressed. The expression of multiple cell-surface mucins
with similar functional roles may explain why Muc1 null mice
show no obvious signs of epithelial pathology (29), although
these mice are also yet to be tested comprehensively with
epithelial challenges. Interestingly, when Muc1 null mice were
removed from a pathogen-free environment, they developed
ocular and reproductive tract bacterial infections, implicating
cell surface mucins in protection from epithelial bacterial in-
fections (30, 31).
In addition to expression in epithelial cells, in situ hybrid-
ization in murine tissues demonstrated substantial expression
of MUC13 in lymphoid tissue associated with the large intes-
tine. Lymphoid tissue expression could have contributed to
MUC13 RNA detection in human RNA samples derived from
normal and malignant intestinal tissues. However, at the pro-
tein level, there was only limited histochemical reactivity of
MUC13 in human gastrointestinal-associated lymphoid tissue,
demonstrating clearly that protein expression levels of MUC13
are highest in epithelial cells.
Our initial biochemical characterization in two colorectal
cancer cell lines demonstrates that MUC13 is predominantly a
cell surface molecule, that it undergoes N- and O-glycosylation,
and that the mucin domain is cleaved from the transmembrane
subunit, as occurs for both MUC1 and MUC4 (13, 14). The
C-terminal subunit containing the cytoplasmic tail is hereto
referred to as the b-subunit using the terminology introduced
for MUC4 (8). The b-subunit appears to undergo homodimer-
ization that is dependent on intrachain disulfide bonds. The
predicted mass of the entire MUC13 polypeptide minus the
signal peptide is ;53 kDa. Western blotting shows that
the 55–58-kDa b-subunit contains the A, B, and C peptide
epitopes. The predicted mass of a minimum C-terminal
polypeptide containing these three epitopes is 31 kDa and
contains three potential sites for N-glycosylation. The immu-
noprecipitated and reduced MUC13 b-subunit was ;55 kDa
and was reduced to 49- and 38-kDa bands following PNGase F
treatment to remove N-linked sugars. Taken together, this
suggests the 55-kDa band represents the N-glycosylated b-sub-
unit of MUC13 containing the cytoplasmic domain, transmem-
brane domain, the C-terminal EGF-like domains, and at least
part of the SEA module (see Fig. 2 for a diagrammatic
representation).
The apparent cleavage of MUC13 needs to be confirmed by
biosynthetic studies. The 120-kDa immunoprecipitated band
reactive with HPA and PNA is most likely to represent the
N-terminal mucin domain containing a-subunit of MUC13.
This band was only just visible in immunoprecipitates of bioti-
nylated cell surface proteins, perhaps due to a tendency for the
a-subunit to disassociate from the b-subunit in detergents, as
has been shown for MUC1 (22). The a-subunit may also show
poor binding to nitrocellulose due to extensive O-glycosylation.
Furthermore, the a-subunit would not be highly biotinylated
inasmuch as, compared with 14 lysine residues in the extracel-
lular domain C-terminal of the A peptide, there are only five
lysine residues N-terminal to the A peptide, and these lie
between EGF1 and the A peptide. The observation that the
a-subunit is weakly biotinylated suggests the cleavage occurs
between the lysine in EGF1 (amino acid 190) and the A peptide.
The predicted mass of an N-terminal MUC13 a-subunit termi-
nating at the A epitope is 22 kDa, the majority of which com-
prises the mucin domain. If the 120-kDa band is this N-termi-
nal a-subunit, then it must be over 80% carbohydrate by
weight, which is not unexpected for a mucin glycoprotein.
Other post-translational modifications could contribute to the
mass of this subunit; for example, a YYY motif near EGF1
(amino acids 203–205) may represent a site of tyrosine
sulfation.
The 520-kDa immunoprecipitated band observed under
non-reducing conditions may represent oligomers of intact
MUC13 molecules. These complexes also appear to contain
another cell surface protein as when reduced a 70–72-kDa
biotinylated band was observed. The 70-kDa protein was
PNGase F-resistant (not N-glycosylated) and did not react
with the HPA or PNA lectins (not O-glycosylated) or with the
A, B, or C MUC13 antisera (not the MUC13 b-subunit). The
70-kDa protein may be an important constituent of the 520-
kDa protein complex, and requires further investigation. Ad-
ditional antibodies reactive with a-subunit epitopes need to
be generated to confirm these conclusions. However, it is
clear that the MUC13 b-subunit undergoes homo-oligomer-
ization into dimers and that oligomerization is dependent on
intrastrand disulfide bonds.
The role of cell surface mucins in epithelial tissues is not
clearly understood. The complexity and level of expression is
greatest in epithelial surfaces exposed to antigenically and
chemically complex luminal environments. Based on knowl-
edge of their structure and expression patterns, it is likely that
these molecules play an important role in barrier function. In2 S. J. Williams and M. A. McGuckin, unpublished observations.
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addition to presenting large extended heavily glycosylated mu-
cin domains on the cell surface, highly conserved structural
features suggest that an ability to shed the extracellular mucin
domain and to report via cytoplasmic domain signaling are
important facets of these cell-surface molecules. The signaling
pathways triggered by cell surface mucins such as MUC13
remain to be elucidated, although it appears that MUC1 can
activate the ras pathway via Grb2 (32) and interact with
b-catenin, an important modulator of cell adhesion and growth
(33, 34). Interactions between secreted mucins and bacteria
have been well characterized (35), and it is possible that inter-
action with bacteria is an important part of cell surface mucin
function. In fact, a recent study utilizing CHO cells stably
expressing Muc1 mucin (36) has demonstrated phosphoryla-
tion of the Muc1cytoplasmic domain following adhesion of
Pseudomonas aeruginosa to the extracellular domain of this
mucin.3
It has been proposed that cell surface EGF-like domain con-
taining mucins can modulate epithelial cell growth via modu-
lation of the c-erbB family of growth factor receptors. Rat Muc4
has been shown to interact with the c-erbB-2 receptor and
promote receptor kinase activity, and cell proliferation, both in
the presence and absence of the c-erbB-2 ligand, neuregulin-1
(15). MUC4, like MUC13, is expressed deep in the crypts of the
colon where cell proliferation occurs.
MUC13 mRNA was expressed by most colorectal cancers
examined, although generally at equivalent or lower levels of
expression than adjacent normal tissue. Immunohistochemis-
try demonstrated heterogeneous expression of MUC13 within
individual cancers. MUC13 may influence tumor growth and
metastasis, as has been shown for both MUC1 (6) and MUC4
(37). Expression of MUC13 on the surface of colorectal cancer
cells may influence growth characteristics via interactions with
c-erbB growth factor receptors, modulate adhesion and inter-
fere with immune recognition. It has been suggested that
mMuc13 expressed on platelets is involved in interaction of
platelets with endothelial cells (38), and, by the same mecha-
nism, MUC13 on cancer cells may interact with endothelial
ligands during metastasis. MUC1 is shed/secreted into the
blood by cancers, particularly those of the breast, lung, and
ovary, and is the antigen measured in several different clini-
cally utilized serum diagnostic tests such as Truquant BR,
CA15.3, MCA, CA549, and CASA (39). MUC13, like MUC1,
may be released from the surface of cancer cells and may
therefore be a useful serum diagnostic target in patients with
gastrointestinal cancers.
MUC13 may also play an important modulatory role in epi-
thelial responses to damage and infection, and in non-malig-
nant epithelial diseases where barrier function and/or mucin
secretion are important, such as inflammatory bowel diseases,
cystic fibrosis (CF), and chronic respiratory diseases. Interest-
ingly, the MUC1 mucin has been demonstrated in animal mod-
els to have a critical influence on gastrointestinal mucus ob-
struction in CF (40). Previously, it had been thought that the
gel-forming mucins were the major contributors to mucus ac-
cumulation in CF. MUC13 has a similar gastrointestinal ex-
pression pattern as MUC1 and is also highly expressed in
tracheal tissue and therefore also warrants investigation as a
potential modulator of mucus accumulation in CF.
It is now apparent that some epithelial transmembrane mu-
cins, like MUC13, are expressed in hemopoietic cells. MUC1
(CD227) is expressed by activated T cells (41), activated den-
dritic cells (42), and bone marrow mononuclear precursor cells
(43). Muc1 null mice have major disturbances to T cell devel-
opment and function.4 Previous studies demonstrated rodent
Muc13 expression in bone marrow precursor cells, and we have
shown expression in spleen, consistent with expression in he-
mopoietic precursor cells. It has been shown that spleen and
bone marrow-derived mMuc13-positive cells selectively prolif-
erate in vitro in response to pokeweed mitogen-stimulated
spleen cell-conditioned medium or recombinant IL-3 (24).
Mouse Muc13 was also identified as being associated with
megakaryocyte maturation and platelet formation (37). Up-
regulation of mMuc13 in a murine megakaryoblastic cell line,
L8057, when differentiating into a megakaryocytic lineage,
suggested mMuc13 could be involved with cell differentiation
and maturation. Overexpression of mMuc13 was found to in-
hibit cell adhesion to fibronectin, suggesting it could act as a
negative regulator of cell adhesion in the megakaryocytic line-
age. We also observed strong expression of mMuc13 in intes-
tine-associated lymphoid tissue, and weaker expression in
lymphoid cells in both the red pulp and follicles of the spleen.
MUC13 is clearly expressed by mature lymphoid cells, and this
requires further characterization.
In summary, we have determined the complete cDNA se-
quence of a novel human mucin gene, MUC13, and shown that
this gene encodes a cell surface and secreted mucin that is most
highly expressed in epithelial tissues but is also found in some
hemopoietic cells. Our future research will concentrate on the
role of the MUC13 mucin protein in non-malignant and malig-
nant epithelial diseases, particularly those of the gastrointes-
tinal tract.
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